New UK Pathway Use Has ‘Far Exceeded Expectations’
Early/Mid-Development Stage Drugs Accounted For Most 1st-Year Requests
Executive Summary
Oncology products accounted for the largest proportion of requests for a UK “innovation passport” last year, with a wide variety of drug sponsors deciding to use the new ILAP, according to the UK regulator, the MHRA.
You may also be interested in...
UK MHRA Says Time For ‘Tough Decisions’ On Entry To Innovative Pathway
The UK regulator wants to revise the broad definition it applies to drugs entering its Innovative Licensing and Access Pathway so that the scheme resembles similar offerings by other regulators, such as the EMA’s PRIME and the US FDA’s Breakthrough Therapy Designation.
The Evolution Of Drug Regulation In Post-Brexit Britain
Regulatory reliance is playing an increasingly important role in gaining marketing authorization in the UK following Brexit. Meanwhile, the country’s unique Innovative Licensing and Access Pathway is attracting growing levels of interest, not just from companies but from regulators and health technology appraisal bodies across the world.
UK Offers To Help ‘Innovation Passport’ Holders Tackle Market Access Challenges
The option of receiving early, joined-up advice from HTA bodies in England, Scotland and Wales is among several tools that companies can use if their product is admitted to the UK’s Innovative Licensing and Access Pathway.